AMBU B Ambu A/S Class B

AMBU APPOINTS NEW CHIEF FINANCIAL OFFICER

AMBU APPOINTS NEW CHIEF FINANCIAL OFFICER

Thomas Frederik Schmidt will step down as CFO of Ambu by 31 December 2023; Henrik Skak Bender named as new CFO, effective 1 January 2024.



Ambu A/S has appointed Henrik Skak Bender as the company’s new Chief Financial Officer and member of the Executive Management, effective 1 January 2024. Henrik succeeds Thomas Frederik Schmidt, who will step down, effective 31 December 2023.



During Thomas’ period as CFO, the financial situation of Ambu has stabilised, the company has returned to positive free cash flow ahead of plan and reduced its gearing to a low level, and first steps have been taken towards strong profitable growth. During the next phase of the strategy, Ambu will zoom in on accelerating growth, while delivering improved profitability. Henrik Skak Bender will take on the CFO leadership during this phase, leveraging his strategic and operational experience from international companies to drive efficiency, agility and growth.



"In the progression of Ambu’s ZOOM IN strategy, I have, together with the Board, decided to bring in a new leadership profile to execute on the next phase of Ambu’s transformation and growth journey. I am convinced that Henrik is the right profile for the CFO role at Ambu, as he brings strategic and operational experience from global companies, as well as the medical device industry. On behalf of myself and the Board, I want to thank Thomas for his contributions to Ambu, and I wish him the best for the future."

BRITT MEELBY JENSEN

Chief Executive Officer at Ambu



STRONG PROFILE WITHIN MEDICAL DEVICES AND GROWTH TRANSFORMATIONS


During the past 20 years, Henrik has worked at leading international companies, such as WS Audiology, Urban Partners, McKinsey & Co and A.P. Moller-Maersk. At the hearing aid company, WS Audiology, he served as CFO and Head of Integration, leading the finance, IT, legal and procurement functions. Prior to that, he served as CFO at Widex, where he was responsible for developing and executing the company’s growth and transformation strategy, together with the rest of the management team.



Most recently, Henrik joins from the asset management company, Urban Partners, where he serves as a member of the executive management, leading the company to grow from a Nordic player with EUR 6bn in assets under management in 2020 to a Northern European player with EUR +20bn in assets under management. At Urban Partners, Henrik held a position as Partner and COO, where he focused on driving and scaling a wide range of functions, including Investor Relations, Finance, IT and Sustainability.



With his entry into Ambu, Henrik is looking forward to returning to the medical devices industry and to making an impact on the company’s growth and transformation journey:



"I am very excited to join Ambu at such a pivotal time in the company’s transformation journey, playing my part in unlocking Ambu’s significant potential. Throughout my career, my drive has been to create sustainable long-term impact by building and leading high-performing teams of people who want to make a real difference. I am looking forward to working with my future Ambu colleagues to deliver on the strategy, as well as engaging with analysts, investors and partners to drive strong long-term stakeholder and shareholder value."

HENRIK SKAK BENDER

Upcoming Chief Financial Officer at Ambu, as of 1 January 2024









Ambu A/S

Baltorpbakken 13

2750 Ballerup

Denmark

Tel.

CVR no.: 63 64 49 19



CONTACT

Investors

Anders Hjort

Head of Investor Relations







Media

Tine Bjørn Schmidt

Head of Corporate Communications



ABOUT AMBU

Ever since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring solutions. Today, we continue to collaborate with leading medical experts to deliver innovations that make a real difference to healthcare professionals and their patients. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, Latin America and the Asia Pacific, 4,500 team members keep Ambu moving forward. For more information, please visit Ambu.com.

Attachment



EN
11/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 1 director

A director at Ambu AS bought 12,500 shares at 118.560DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Ambu A/S: Reporting of transactions made by persons discharging manage...

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.   The attached document discloses the data of the transactions made in Ambu shares.  Attachment

 PRESS RELEASE

GRANT OF PERFORMANCE SHARE UNITS

GRANT OF PERFORMANCE SHARE UNITS Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees.  The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT marg...

Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK130.00) - Strong Q1 suggests promising 2024

With a c20% EBIT beat driven by the top line and profitability, Q1 showed Ambu is off to a strong start to 2023/24. However, the guidance was maintained and remains conservative in our view, while recent price rises to the legacy business and more reimbursement for the aScope 5 leave further upside potential. We reiterate our BUY and have raised our target price to DKK130 (120).

 PRESS RELEASE

INTERIM REPORT FOR Q1 2023/24

INTERIM REPORT FOR Q1 2023/24 In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive free cash flow of DKK 135m, we are off to a solid start ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch